How big is the Ankylosing Spondylitis Treatment Market?

The Ankylosing Spondylitis Treatment Market size is expected to reach USD 6.64 billion in 2024 and grow at a CAGR of 7.75% to reach USD 9.72 billion by 2029. Read More

What is the current Ankylosing Spondylitis Treatment Market size?

In 2024, the Ankylosing Spondylitis Treatment Market size is expected to reach USD 6.64 billion. Read More

Who are the key players in Ankylosing Spondylitis Treatment Market?

Novartis AG, AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH and UCB S.A. are the major companies operating in the Ankylosing Spondylitis Treatment Market. Read More

Which is the fastest growing region in Ankylosing Spondylitis Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Ankylosing Spondylitis Treatment Market?

In 2024, the North America accounts for the largest market share in Ankylosing Spondylitis Treatment Market. Read More

What years does this Ankylosing Spondylitis Treatment Market cover, and what was the market size in 2023?

In 2023, the Ankylosing Spondylitis Treatment Market size was estimated at USD 6.13 billion. The report covers the Ankylosing Spondylitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Ankylosing Spondylitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Ankylosing Spondylitis Treatment Market Trends

Statistics for the 2023 & 2024 Ankylosing Spondylitis Treatment market trends, created by Mordor Intelligence™ Industry Reports. Ankylosing Spondylitis Treatment trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Ankylosing Spondylitis Treatment Industry

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Rising Significance of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

First-Line Treatment: NSAIDs are increasingly recognized as essential in managing ankylosing spondylitis due to their efficacy in reducing pain and inflammation. As the first-line treatment, NSAIDs remain popular due to their affordability and widespread availability. Industry analysis indicates growing demand for NSAIDs, driven by the rising incidence of ankylosing spondylitis and the immediate relief these medications provide.
Ongoing Innovation: The NSAIDs segment is expected to continue growing, fueled by ongoing research into new formulations with enhanced efficacy and fewer side effects. The introduction of potent NSAIDs with improved safety profiles is anticipated to increase their market value. Despite the increasing interest in biologics, NSAIDs are projected to maintain their significance in ankylosing spondylitis pain management strategies.

Market Expansion through Strategic Collaborations

Product Launches and Approvals: Strategic initiatives such as product launches and approvals are driving the growth of the NSAIDs segment. For instance, the FDA’s approval of RINVOQ (upadacitinib) in 2022 as an oral treatment for ankylosing spondylitis highlights the ongoing innovation within this segment. These developments are expected to drive demand and solidify NSAIDs' role in the ankylosing spondylitis treatment market.

Ankylosing Spondylitis Treatment: Number of Ankylosing Spondylitis Clinical Trials, By Phase, Global, January 2020 - January 2023

Understand The Key Trends Shaping This Market

Download PDF

North America's Dominance in the Ankylosing Spondylitis Treatment Market

Market Leadership in North America

Advanced Healthcare Infrastructure: North America, particularly the United States, is expected to maintain its dominant position in the ankylosing spondylitis treatment market due to its advanced healthcare infrastructure and high disease awareness. The availability of cutting-edge ankylosing spondylitis medication, including biologics and TNF inhibitors, supports the region’s market leadership.
Innovative Treatments: The continuous development and approval of innovative treatments further fuel North America’s market growth. For example, Coherus Biosciences' FDA approval of Yusimry (adalimumab) in 2021 exemplifies the region’s commitment to advancing ankylosing spondylitis treatment options.

Supportive Reimbursement Policies and Patient Assistance

Financial Assistance Programs: The growth of the ankylosing spondylitis treatment market in North America is bolstered by favorable reimbursement policies and patient assistance programs. Organizations like the Patient Access Network (PAN) Foundation provide financial assistance, reducing the economic burden of treatment and ensuring access to advanced therapies.